BofA lowered the firm’s price target on Crescent Capital BDC to $19 from $20 and keeps a Buy rating on the shares. Crescent Capital reported another solid quarter following record core earnings last quarter and the firm continues to view Crescent as well-positioned to gain share and deliver attractive risk-adjusted returns, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCAP: